All news (page 13)

• 

  13 June 2026

  Genmab: Epcoritamab shows high response rates in elderly first‑line DLBCL with mono and R‑mini‑CHOP regimens

  Fixed‑duration subcutaneous epcoritamab produced rapid, durable responses and high MRD negativity in elderly newly diagnosed DLBCL patients ineligible for full‑dose anthracycline therapy.
• 

  12 June 2026

  SunGas ends Beaver Lake bio-methanol project

  Planned wood-fiber-to-low-carbon-methanol plant near Alexandria will not proceed, citing slow market uptake, CCS and regulatory/financing uncertainty.
• 

  12 June 2026

  Roche VENTANA PTEN (SP218) FDA-cleared as PTEN companion diagnostic in prostate cancer

  First FDA-cleared IHC companion diagnostic to detect PTEN protein loss and select patients for capivasertib (TRUQAP) plus abiraterone therapy.
• 

  12 June 2026

  Merck: FDA approves KEYTRUDA and KEYTRUDA QLEX with WELIREG for adjuvant ccRCC

  FDA cleared PD‑1 plus HIF‑2α adjuvant regimens after Phase 3 showed 28% lower recurrence risk and 81% vs 74% 24‑month DFS; notable anemia, hypoxia and treatment discontinuations.
• 

  12 June 2026

  BASF’s Tinosorb S (bemotrizinol) approved by FDA as first new U.S. sunscreen active in 27 years

  FDA clears bemotrizinol, a broad‑spectrum, photostable UV filter that enables longer‑lasting, stronger UVA/UVB protection and improved formulation stability.
• 

  12 June 2026

  Mitsui Chemicals to acquire Ultradent via U.S. holding company

  Acquiring Utah-based dental-products maker for $900M; will combine Ultradent with Kulzer, move oral-care HQ to the U.S., and target closing in Sept 2026.

• 

  12 June 2026

  Chugai files Tecentriq for maintenance therapy after definitive chemoradiotherapy in locally advanced esophageal cancer

  Submission seeks approval of an anti‑PD‑L1 agent as maintenance therapy after definitive chemoradiotherapy, supported by SKYSCRAPER‑07 Phase III interim results.
• 

  12 June 2026

  GSK’s momelotinib gains orphan drug status in US and EU for VEXAS

  Orphan designations back development of momelotinib for VEXAS; ATLAS phase II/III underway with design to be shown at EHA 2026.
• 

  12 June 2026

  Sinopec and Inner Mongolia sign comprehensive strategic cooperation agreement

  Regional government and state energy group agree to deepen project-level cooperation, align development plans and expand projects including hydrogen, carbon fiber and coal-chemicals.
• 

  11 June 2026

  Air Liquide and ArianeGroup renew contracts to support Ariane 6 operations

  Secures cryogenic equipment through flight 42 and a renewed propellant and fluids supply to back Ariane 6 industrial ramp-up.
• 

  11 June 2026

  Repsol and Masdar partner on €849m, 705 MW Spanish renewables portfolio

  Masdar to buy 49.99% stake in a €849m portfolio with 705 MW operational capacity and >565 MW hybridization pipeline; deal expected to close late 2026 pending approvals.
• 

  11 June 2026

  WuXi Biologics included in S&P Global Sustainability Yearbook (China) for fourth consecutive year

  Placed in S&P Global CSA Global Top 1% and included in both the Global and China Sustainability Yearbooks; company emphasises Green CRDMO solutions.
• 

  11 June 2026

  Genmab: Epcoritamab plus R2 shows consistent benefit across EPCORE FL‑1 subgroups

  Post‑hoc subgroup analysis of the Phase 3 EPCORE FL‑1 shows epcoritamab+rituximab+lenalidomide delivers consistent PFS, ORR and CRR gains with a manageable safety profile across risk and fitness subgroups.
• 

  11 June 2026

  Novo Nordisk: Wegovy pill approved in UK as first daily GLP-1 weight-loss tablet in Europe

  Daily 25 mg semaglutide tablet approved as adjunct to diet and exercise for adults with obesity or overweight plus a weight‑related condition; private prescriptions expected soon.
• 

  11 June 2026

  SPIE Belgium to integrate 304 MWh battery park in Auvelais

  304 MWh, 4‑hour storage to inject 76 MVA into the 150 kV grid; 82 Megapack containers; civil works to summer 2026 and commissioning end Jan 2027.
• 

  11 June 2026

  Johnson & Johnson’s IMAAVY shows rapid, durable hemoglobin gains in Phase 2/3 wAIHA trial

  Nipocalimab 30 mg/kg produced rapid hemoglobin rises and ~3× more durable responders versus placebo at 24 weeks, with early fatigue improvement and reduced steroid use.
• 

  11 June 2026

  Takeda's zasocitinib outperforms deucravacitinib in Phase 3 psoriasis head-to-head

  Once-daily oral TYK2 inhibitor showed statistical superiority to deucravacitinib for PASI100 and key secondary endpoints, with >35% achieving complete skin clearance at week 16.
• 

  11 June 2026

  Exolum starts operations at Madeira Airport, to invest €4.5m+ in fuel facilities

  Will expand storage to 1,300 m³, upgrade hydrant network and invest over €4.5m by 2029 under a 7‑year contract (option to 9).
• 

  11 June 2026

  European Commission secures stronger MSR safeguards for ETS2 (buildings & road transport)

  Strengthened MSR for ETS2 doubles allowance injections, extends reserve validity past 2030, enables earlier gradual releases, and starts early auctions in 2027 with a €3bn frontloading facility.
• 

  11 June 2026

  Evonik launches low‑carbon peracetic acid for Europe

  Peracetic acid produced using bio-based acetic acid and low‑carbon hydrogen peroxide; mass‑balance accounting lets customers lower Scope 3 emissions transparently.
• 

  11 June 2026

  Aurubis Hamburg opens high-capacity RDE exhaust and filter system

  Expanded RDE system doubles diffuse-emission reduction to ~80%, treats >1.6M m3/hr, returns captured metals to production; part of a €115m programme with KfW backing.
• 

  11 June 2026

  Air Liquide and ArianeGroup renew industrial partnership with two Ariane 6 contracts

  Contracts cover cryogenic manufacturing equipment through flight 42 and a three‑year supply of propellants and ground gases for Ariane 6 operations.
• 

  11 June 2026

  MOL concludes talks with Serbian government on NIS shareholders' agreement

  Includes Pancevo refinery, retail network and E&P assets; supplies 80% of Serbia's fuel needs and has stations in Bosnia, Bulgaria and Romania; seller/authority talks continue.
• 

  10 June 2026

  Saipem awarded onshore EPC contract for Uthmaniyah Gas Compression Plant in Saudi Arabia

  EPC for Uthmaniyah compression plant to extend field life; ~42-month term; contract share ≈€900m; delivered via Saudi JV under National EPC Champion Program.
• 

  10 June 2026

  Cryocap FG pilot starts at Holcim CaptureLab

  Modular adsorption–cryogenic unit pre-treats and preconcentrates cement flue gas to remove impurities and enable retrofit capture without major plant changes.
• 

  10 June 2026

  Genentech: FDA grants Priority Review for Tecentriq plus chemotherapy in stage III dMMR/MSI‑H colon cancer

  FDA accepted an sBLA for adjuvant PD‑L1 therapy plus chemotherapy in stage III dMMR/MSI‑H colon cancer; agency decision expected Oct 9, 2026.
• 

  10 June 2026

  Aptar N‑Sorb patent allowed by USPTO for packaging-based nitrosamine mitigation

  USPTO allowed a patent for N‑Sorb, a packaging material that reduces nitrosamines across multiple APIs and may support FDA Orange Book strategies.
• 

  10 June 2026

  EBN, Eni, Gasunie, OGE, Shell and TotalEnergies sign MoU on Delta Rhine Corridor CO₂ pipeline

  Cross-border CO₂ pipeline to link North Rhine‑Westphalia industrial clusters to Dutch North Sea storage; target operation 2033 with initial Dutch sections in 2032.
• 

  10 June 2026

  Worley completes FEED for Alfanar Lighthouse Green Fuels SAF plant

  Engineering milestone clears path to FID end‑2027 and commercial operations in 2032; plant to produce 180 ML SAF and 30 ML renewable naphtha annually.
• 

  10 June 2026

  dsm-firmenich: FDA approves bemotrizinol (PARSOL® Shield) for U.S. suncare

  FDA clears bemotrizinol (PARSOL® Shield), the first new U.S. sunscreen active in 25+ years, enabling broad‑spectrum, photostable formulas with low‑concentration efficacy.